KRAS and non-small cell lung carcinoma: Promising results in phase I/II clinical trials in patients suffering from KRAS-driven NSCLC evaluating sotorasib, a highly selective and irreversible inhibitor leading to trapping of KRAS in an inactive GDP-bound state, have led to a recent approval by the Food and Drug Administration (FDA) (114–119).